Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial.

Area of Science:

• Periodontology
• Nutritional Science
• Inflammation Research

Background:

• Periodontitis is a prevalent chronic inflammatory condition linked to bacterial infection, leading to bone loss and tooth loss.
• Long-chain omega-3 fatty acids, like docosahexaenoic acid (DHA), have demonstrated efficacy in reducing periodontitis in animal models.
• Systemic inflammation is a known consequence of periodontitis, impacting overall health.

Purpose of the Study:

• To investigate the therapeutic potential of docosahexaenoic acid (DHA) supplementation combined with low-dose aspirin in treating periodontitis in humans.
• To evaluate the effects of DHA and aspirin on periodontal clinical parameters and inflammatory markers.

Main Methods:

• A 3-month, double-blind, placebo-controlled, parallel trial involving 55 adults with moderate periodontitis.
• Participants were randomized to receive 2,000 mg of DHA or a placebo, alongside 81 mg of aspirin daily.
• Outcomes included changes in pocket depth, gingival index, plaque index, bleeding on probing, and inflammatory markers (hsCRP, IL-6, IL-1β) in gingival crevicular fluid and plasma.

Main Results:

• DHA supplementation significantly decreased mean pocket depth (p = .03) and gingival index (p = .04).
• No significant changes were observed in plaque index or bleeding on probing.
• Significant reductions in gingival crevicular fluid hsCRP (p = .03) and IL-1β (p = .02) were noted in the DHA group compared to placebo.

Conclusions:

• Aspirin-triggered DHA supplementation demonstrates significant therapeutic efficacy in improving periodontal outcomes for individuals with periodontitis.
• This combination therapy may offer a novel approach to managing periodontitis by reducing local inflammation and clinical signs.
• Further research is warranted to confirm these findings and explore long-term effects.